Published in J Infect Dis on July 16, 2001
Preexposure chemoprophylaxis for HIV prevention in men who have sex with men. N Engl J Med (2010) 50.17
Prevention of rectal SHIV transmission in macaques by daily or intermittent prophylaxis with emtricitabine and tenofovir. PLoS Med (2008) 7.46
Tenofovir disoproxil fumarate for prevention of HIV infection in women: a phase 2, double-blind, randomized, placebo-controlled trial. PLoS Clin Trials (2007) 4.93
Preexposure prophylaxis and predicted condom use among high-risk men who have sex with men. J Acquir Immune Defic Syndr (2010) 3.58
Potential impact of antiretroviral chemoprophylaxis on HIV-1 transmission in resource-limited settings. PLoS One (2007) 2.84
Sexual risk behaviors and acceptability of HIV pre-exposure prophylaxis among HIV-negative gay and bisexual men in serodiscordant relationships: a mixed methods study. AIDS Patient Care STDS (2011) 2.13
Antiretroviral agents used by HIV-uninfected persons for prevention: pre- and postexposure prophylaxis. Clin Infect Dis (2010) 2.07
Clinical potential of the acyclic nucleoside phosphonates cidofovir, adefovir, and tenofovir in treatment of DNA virus and retrovirus infections. Clin Microbiol Rev (2003) 1.91
Biological effects of short-term or prolonged administration of 9-[2-(phosphonomethoxy)propyl]adenine (tenofovir) to newborn and infant rhesus macaques. Antimicrob Agents Chemother (2004) 1.90
Chronic administration of tenofovir to rhesus macaques from infancy through adulthood and pregnancy: summary of pharmacokinetics and biological and virological effects. Antimicrob Agents Chemother (2008) 1.79
Immunization of newborn rhesus macaques with simian immunodeficiency virus (SIV) vaccines prolongs survival after oral challenge with virulent SIVmac251. J Virol (2003) 1.53
Post-exposure prophylaxis of HIV infection in healthcare workers: recommendations for the European setting. Eur J Epidemiol (2004) 1.50
Criteria for drugs used in pre-exposure prophylaxis trials against HIV infection. PLoS Med (2006) 1.34
CD8+-cell-mediated suppression of virulent simian immunodeficiency virus during tenofovir treatment. J Virol (2004) 1.25
Preexposure prophylaxis for HIV prevention. Curr HIV/AIDS Rep (2011) 1.24
Virulence and reduced fitness of simian immunodeficiency virus with the M184V mutation in reverse transcriptase. J Virol (2002) 1.23
Evidence for persistent, occult infection in neonatal macaques following perinatal transmission of simian-human immunodeficiency virus SF162P3. J Virol (2006) 1.15
Media reporting of tenofovir trials in Cambodia and Cameroon. BMC Int Health Hum Rights (2005) 1.15
Pharmacokinetics and safety of single-dose tenofovir disoproxil fumarate and emtricitabine in HIV-1-infected pregnant women and their infants. Antimicrob Agents Chemother (2011) 1.09
AIDS vaccines and preexposure prophylaxis: is synergy possible? AIDS Res Hum Retroviruses (2010) 1.07
Structured treatment interruptions with tenofovir monotherapy for simian immunodeficiency virus-infected newborn macaques. J Virol (2006) 1.05
Antiretrovirals for primary HIV prevention: the current status of pre- and post-exposure prophylaxis. Curr HIV/AIDS Rep (2015) 1.04
Pharmacokinetics of tenofovir in breast milk of lactating rhesus macaques. Antimicrob Agents Chemother (2005) 1.00
Use of non-occupational post-exposure prophylaxis does not lead to an increase in high risk sex behaviors in men who have sex with men participating in the EXPLORE trial. AIDS Behav (2010) 0.99
The rhesus macaque pediatric SIV infection model - a valuable tool in understanding infant HIV-1 pathogenesis and for designing pediatric HIV-1 prevention strategies. Curr HIV Res (2009) 0.97
Drug-susceptible HIV-1 infection despite intermittent fixed-dose combination tenofovir/emtricitabine as prophylaxis is associated with low-level viremia, delayed seroconversion, and an attenuated clinical course. J Acquir Immune Defic Syndr (2008) 0.96
A therapeutic SIV DNA vaccine elicits T-cell immune responses, but no sustained control of viremia in SIVmac239-infected rhesus macaques. AIDS Res Hum Retroviruses (2008) 0.95
Practical guidance for nonoccupational postexposure prophylaxis to prevent HIV infection: an editorial review. AIDS (2014) 0.92
Prevention of the sexual transmission of HIV-1: preparing for success. J Int AIDS Soc (2008) 0.90
A vaccine against CCR5 protects a subset of macaques upon intravaginal challenge with simian immunodeficiency virus SIVmac251. J Virol (2013) 0.87
AIDS: Drugs that prevent HIV infection. Nature (2011) 0.84
A drug evaluation of 1% tenofovir gel and tenofovir disoproxil fumarate tablets for the prevention of HIV infection. Expert Opin Investig Drugs (2012) 0.82
Animal and human mucosal tissue models to study HIV biomedical interventions: can we predict success? J Int AIDS Soc (2015) 0.77
Recent key advances in human immunodeficiency virus medicine and implications for China. AIDS Res Ther (2010) 0.76
The microbicide tenofovir does not inhibit nucleic acid amplification tests for detection of Chlamydia trachomatis and Neisseria gonorrhoeae in urine samples. J Clin Microbiol (2007) 0.75
Optimal HIV Postexposure Prophylaxis Regimen Completion With Single Tablet Daily Elvitegravir/Cobicistat/Tenofovir Disoproxil Fumarate/Emtricitabine Compared With More Frequent Dosing Regimens. J Acquir Immune Defic Syndr (2017) 0.75
Prevention of SIV infection in macaques by (R)-9-(2-phosphonylmethoxypropyl)adenine. Science (1995) 9.48
Viral dynamics of primary viremia and antiretroviral therapy in simian immunodeficiency virus infection. J Virol (1997) 3.79
Influenza neuraminidase inhibitors possessing a novel hydrophobic interaction in the enzyme active site: design, synthesis, and structural analysis of carbocyclic sialic acid analogues with potent anti-influenza activity. J Am Chem Soc (1997) 3.69
Role of CD8(+) lymphocytes in control of simian immunodeficiency virus infection and resistance to rechallenge after transient early antiretroviral treatment. J Virol (2001) 3.40
Anti-human immunodeficiency virus activity and cellular metabolism of a potential prodrug of the acyclic nucleoside phosphonate 9-R-(2-phosphonomethoxypropyl)adenine (PMPA), Bis(isopropyloxymethylcarbonyl)PMPA. Antimicrob Agents Chemother (1998) 3.01
Macrophage are the principal reservoir and sustain high virus loads in rhesus macaques after the depletion of CD4+ T cells by a highly pathogenic simian immunodeficiency virus/HIV type 1 chimera (SHIV): Implications for HIV-1 infections of humans. Proc Natl Acad Sci U S A (2001) 2.96
Rhesus macaques previously infected with simian/human immunodeficiency virus are protected from vaginal challenge with pathogenic SIVmac239. J Virol (1997) 2.59
Oral administration of a prodrug of the influenza virus neuraminidase inhibitor GS 4071 protects mice and ferrets against influenza infection. Antimicrob Agents Chemother (1998) 2.44
Viremia control following antiretroviral treatment and therapeutic immunization during primary SIV251 infection of macaques. Nat Med (2000) 2.33
Containment of simian immunodeficiency virus infection: cellular immune responses and protection from rechallenge following transient postinoculation antiretroviral treatment. J Virol (2000) 2.24
A partially attenuated simian immunodeficiency virus induces host immunity that correlates with resistance to pathogenic virus challenge. J Virol (1994) 2.23
9-[2-(Phosphonomethoxy)propyl]adenine therapy of established simian immunodeficiency virus infection in infant rhesus macaques. Antimicrob Agents Chemother (1996) 2.15
Effects of (R)-9-(2-phosphonylmethoxypropyl)adenine monotherapy on chronic SIV infection in macaques. AIDS Res Hum Retroviruses (1997) 2.12
Development of simian immunodeficiency virus isolation, titration, and neutralization assays which use whole blood from rhesus monkeys and an antigen capture enzyme-linked immunosorbent assay. J Clin Microbiol (1991) 2.08
Gag-specific cytotoxic responses to HIV type 1 are associated with a decreased risk of progression to AIDS-related complex or AIDS. AIDS Res Hum Retroviruses (1995) 2.03
Genetic and biological comparisons of pathogenic and nonpathogenic molecular clones of simian immunodeficiency virus (SIVmac). AIDS Res Hum Retroviruses (1992) 1.92
Route of simian immunodeficiency virus inoculation determines the complexity but not the identity of viral variant populations that infect rhesus macaques. J Virol (2001) 1.75
Identification of GS 4104 as an orally bioavailable prodrug of the influenza virus neuraminidase inhibitor GS 4071. Antimicrob Agents Chemother (1998) 1.72
Passive immunization of newborn rhesus macaques prevents oral simian immunodeficiency virus infection. J Infect Dis (1998) 1.71
Viruses perturb lymphocyte functions: selected principles characterizing virus-induced immunosuppression. Annu Rev Immunol (1987) 1.71
Identification of viral determinants of macrophage tropism for simian immunodeficiency virus SIVmac. J Virol (1991) 1.71
Immune response of rhesus macaques to recombinant simian immunodeficiency virus gp130 does not protect from challenge infection. J Virol (1993) 1.68
Two doses of PMPA protect newborn macaques against oral simian immunodeficiency virus infection. AIDS (1998) 1.58
Metabolism and in vitro antiretroviral activities of bis(pivaloyloxymethyl) prodrugs of acyclic nucleoside phosphonates. Antimicrob Agents Chemother (1993) 1.54
Antiviral cytotoxic T lymphocytes in vaginal mucosa of simian immunodeficiency virus-infected rhesus macaques. J Immunol (1995) 1.52
Simian immunodeficiency virus (SIV) infection of infant rhesus macaques as a model to test antiretroviral drug prophylaxis and therapy: oral 3'-azido-3'-deoxythymidine prevents SIV infection. Antimicrob Agents Chemother (1992) 1.51
Rheological properties of ice cream mixes and frozen ice creams containing fat and fat replacers. J Dairy Sci (2000) 1.48
Administration of 9-[2-(phosphonomethoxy)propyl]adenine (PMPA) for prevention of perinatal simian immunodeficiency virus infection in rhesus macaques. AIDS Res Hum Retroviruses (1998) 1.46
Transient early post-inoculation anti-retroviral treatment facilitates controlled infection with sparing of CD4+ T cells in gut-associated lymphoid tissues in SIVmac239-infected rhesus macaques, but not resistance to rechallenge. J Med Primatol (2003) 1.45
Synthesis, hybridization properties and antiviral activity of lipid-oligodeoxynucleotide conjugates. Nucleic Acids Res (1990) 1.32
Viral factors determine progression to AIDS in simian immunodeficiency virus-infected newborn rhesus macaques. J Virol (1995) 1.31
Administration of 9-[2-(R)-(phosphonomethoxy)propyl]adenine (PMPA) to gravid and infant rhesus macaques (Macaca mulatta): safety and efficacy studies. J Acquir Immune Defic Syndr Hum Retrovirol (1999) 1.31
The tertiary structure of a DNA aptamer which binds to and inhibits thrombin determines activity. Biochemistry (1993) 1.27
Antiretroviral efficacy and pharmacokinetics of oral bis(isopropyloxycarbonyloxymethyl)-9-(2-phosphonylmethoxypropyl)adenine in mice. Antimicrob Agents Chemother (1998) 1.26
Detection of simian immunodeficiency virus DNA in macrophages from infected rhesus macaques. J Med Primatol (1992) 1.26
Viruses disrupt functions of human lymphocytes. II. Measles virus suppresses antibody production by acting on B lymphocytes. J Exp Med (1986) 1.24
Disarming flu viruses. Sci Am (1999) 1.23
Protective attenuated lentivirus immunization induces SIV-specific T cells in the genital tract of rhesus monkeys. Mucosal Immunol (2008) 1.22
Nasal immunization of nonhuman primates with simian immunodeficiency virus p55gag and cholera toxin adjuvant induces Th1/Th2 help for virus-specific immune responses in reproductive tissues. J Immunol (1998) 1.21
In vitro macrophage tropism of pathogenic and nonpathogenic molecular clones of simian immunodeficiency virus (SIVmac). Virology (1991) 1.20
Immediate zidovudine treatment protects simian immunodeficiency virus-infected newborn macaques against rapid onset of AIDS. Antimicrob Agents Chemother (1995) 1.18
Vaccination of pregnant macaques protects newborns against mucosal simian immunodeficiency virus infection. J Infect Dis (1996) 1.17
Enhanced cellular immune response and reduced CD8(+) lymphocyte apoptosis in acutely SIV-infected Rhesus macaques after short-term antiretroviral treatment. Virology (2001) 1.12
The nef gene of simian immunodeficiency virus SIVmac1A11. J Virol (1992) 1.11
Postischemic administration of adenosine amine congener (ADAC): analysis of recovery in gerbils. Eur J Pharmacol (1996) 1.11
Anatomic site and immune function correlate with relative cytokine mRNA expression levels in lymphoid tissues of normal rhesus macaques. Cytokine (2001) 1.11
9-[2-(Phosphonomethoxy)propyl]adenine (PMPA) therapy prolongs survival of infant macaques inoculated with simian immunodeficiency virus with reduced susceptibility to PMPA. Antimicrob Agents Chemother (1999) 1.09
Functional and immunological characterization of SIV envelope glycoprotein produced in genetically engineered mammalian cells. AIDS Res Hum Retroviruses (1991) 1.09
Antiviral treatment normalizes neurophysiological but not movement abnormalities in simian immunodeficiency virus-infected monkeys. J Clin Invest (2000) 1.07
Antiretroviral activity and pharmacokinetics in mice of oral bis(pivaloyloxymethyl)-9-(2-phosphonylmethoxyethyl)adenine, the bis(pivaloyloxymethyl) ester prodrug of 9-(2-phosphonylmethoxyethyl)adenine. Antimicrob Agents Chemother (1996) 1.07
Antiviral CD8+ T cells in the genital tract control viral replication and delay progression to AIDS after vaginal SIV challenge in rhesus macaques immunized with virulence attenuated SHIV 89.6. J Intern Med (2009) 1.07
Thermal denaturation profiles and gel mobility shift analysis of oligodeoxynucleotide triplexes. Nucleic Acids Res (1990) 1.06
Fatal immunopathogenesis by SIV/HIV-1 (SHIV) containing a variant form of the HIV-1SF33 env gene in juvenile and newborn rhesus macaques. Virology (1999) 1.06
The origin and control of pandemic influenza. Perspect Biol Med (2000) 1.06
SIV/HIV Nef recombinant virus (SHIVnef) produces simian AIDS in rhesus macaques. Virology (1999) 1.02
Preexposure prophylaxis with 9-(2-phosphonylmethoxyethyl)adenine against simian immunodeficiency virus infection in macaques. J Infect Dis (1994) 1.02
Post-exposure chemoprophylaxis (PECP) against SIV infection of macaques as a model for protection from HIV infection. J Med Primatol (2000) 1.00
Virus-induced immunosuppression is linked to rapidly fatal disease in infant rhesus macaques infected with simian immunodeficiency virus. Pediatr Res (1996) 0.99
Minireview: nucleotide prodrugs. Antiviral Res (1995) 0.99
Composition and optical properties of reaction centre core complexes from the green sulfur bacteria Prosthecochloris aestuarii and Chlorobium tepidum. Photosynth Res (2000) 0.98
Modeling glucose and water dynamics in human skin. Diabetes Technol Ther (2008) 0.97
Cleavage of single stranded oligonucleotides by EcoRI restriction endonuclease. Nucleic Acids Res (1987) 0.96
Importance of the intracytoplasmic domain of the simian immunodeficiency virus (SIV) envelope glycoprotein for pathogenesis. Virology (1998) 0.96
Sialylation lessens the infectivity of Neisseria gonorrhoeae MS11mkC. J Infect Dis (1996) 0.95
Pyruvate dehydrogenase complex deficiency as a cause of subacute necrotizing encephalopathy (Leigh disease). Pediatrics (1987) 0.95
A zidovudine-resistant simian immunodeficiency virus mutant with a Q151M mutation in reverse transcriptase causes AIDS in newborn macaques. Antimicrob Agents Chemother (1997) 0.94
Chronic administration of adenosine A3 receptor agonist and cerebral ischemia: neuronal and glial effects. Eur J Pharmacol (1999) 0.94
Reduction of postischemic brain damage and memory deficits following treatment with the selective adenosine A1 receptor agonist. Eur J Pharmacol (1996) 0.92
Lasting effects of transient postinoculation tenofovir [9-R-(2-Phosphonomethoxypropyl)adenine] treatment on SHIV(KU2) infection of rhesus macaques. Virology (2000) 0.91
Characterization of beta-conglycinin and glycinin soy protein fractions from four selected soybean genotypes. J Agric Food Chem (2001) 0.91
Probing structural factors stabilizing antisense oligonucleotide duplexes: NMR studies of a DNA.DNA duplex containing a formacetal linkage. Biochemistry (1992) 0.91
Intracranial haemorrhage as initial presentation of severe haemophilia B: case report and review of Mayo Clinic Comprehensive Hemophilia Center experience. Haemophilia (2005) 0.91
Fetal or neonatal infection with attenuated simian immunodeficiency virus results in protective immunity against oral challenge with pathogenic SIVmac251. Virology (1996) 0.91
New series of potent, orally bioavailable, non-peptidic cyclic sulfones as HIV-1 protease inhibitors. J Med Chem (1996) 0.90
Protection against ischemic damage by adenosine amine congener, a potent and selective adenosine A1 receptor agonist. Eur J Pharmacol (1999) 0.89
Neurologic complications in galactosemia. Pediatr Neurol (1992) 0.88
Energy transfer and charge separation in the purple non-sulfur bacterium Roseospirillum parvum. Biochim Biophys Acta (2000) 0.87
Central hypoventilation syndrome in pyruvate dehydrogenase complex deficiency. Pediatrics (1984) 0.87
Polypeptides p40, pOM2, and pAngR are required for iron uptake and for virulence of the marine fish pathogen Vibrio anguillarum 775. J Bacteriol (1991) 0.87